The amalgamation of Cytiva's pioneering technologies with LevitasBio's cutting-edge solutions seeks to streamline single-cell workflows, offering invaluable time-saving benefits for academic researchers. By integrating the VIA Extractor and LeviCell system, this collaboration addresses critical challenges in sample preparation, mitigating single-cell damage and stress, thereby ensuring the integrity of cellular samples.

Empowering Breakthrough Discoveries

Stephen Bell, President of Discovery & Medical at Cytiva, expressed enthusiasm about the shared vision driving this collaboration. "Our collaboration is rooted in the shared goal of enabling breakthrough discoveries in Life Sciences research that advance and accelerate therapeutic developments," stated Bell. "By combining the strengths of our products with LevitasBio, we aim to empower researchers with a more efficient and gentle approach to sample preparation."

Pioneering Advances in Single-Cell Analysis

Single-cell analysis stands as a cornerstone in propelling therapeutic approaches forward, particularly in the realm of cancer research. Leveraging the expertise and technologies of both companies, Cytiva and LevitasBio endeavor to craft a streamlined, semi-automated workflow solution. This revolutionary approach promises to minimize single-cell damage and stress, bolstering overall single-cell health—a crucial factor in generating viable samples for subsequent genetic studies and downstream cell-based assays.

Martin Pieprzyk, CEO of LevitasBio, underscored the transformative potential of this collaboration. "The VIA Extractor and LeviCell platform offers a more complete approach to tissue dissociation and single-cell suspension cleanup," affirmed Pieprzyk. "Through this pioneering effort, we're taking a significant step towards facilitating breakthroughs in research and translational applications, aligning with our commitment to driving innovation in the life sciences industry."

Advancing Personalized Medicine and Scientific Discovery

The implications of this collaboration extend far beyond the laboratory, with profound implications for personalized medicine, oncology research, and scientific discovery at large. By revolutionizing single-cell workflows, Cytiva and LevitasBio are poised to catalyze advancements that illuminate disease mechanisms, identify therapeutic targets, and accelerate the development of life-saving treatments.

As the partnership between Cytiva and LevitasBio continues to evolve, the scientific community eagerly anticipates the transformative impact it will have on the future of single-cell analysis and therapeutic development.